CureVac welcomes Myriam Mendila as Chief Development Officer

mRNA specialist CureVac has welcomed Myriam Mendila as its new Chief Development Officer.

Myriam Mendila, MD, has more than 20 years of global experience in product development, medical affairs, pharmacovigilance and healthcare compliance as well as global product strategy, including commercial strategy at Roche, Genentech and Novartis.

Over the last 5 years, she has held the position of Chief Medical Officer Oncology and Global Head of Oncology Medical Affairs at Novartis, being responsible for the Medical Affairs strategy and related activities across the overall oncology portfolio at Novartis. Myriam earned her medical degree and subsequently doctoral degree from the Medical University of Hannover, Germany.

Mendila takes over the role from Klaus Edvardsen, who left the company in June last year. Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, has been acting as interim Chief Development Officer.